Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. 01875
01875 logo

01875 Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy TOT BIOPHARM-B (01875) Today? Analysis, Price Targets, and 2026 Outlook.

No data

No data

No data

No data

Growth

Profitability

Efficiency

Wall Street analysts forecast 01875 stock price to rise
0 Analyst Rating
0
Wall Street analysts forecast 01875 stock price to rise
0 Buy
0 Hold
0 Sell
0
Current: 3.600
sliders
Low
0
Averages
0
High
0
0
Current: 3.600
sliders
Low
0
Averages
0
High
0
M Stanley
M Stanley
Overweight
maintain
$83 -> $80
AI Analysis
2026-07-06
New
Reason
M Stanley
M Stanley
Price Target
$83 -> $80
AI Analysis
2026-07-06
New
maintain
Overweight
Reason
M Stanley lowered its earnings forecasts for WUXI XDC for 2026-2030 by about 0-7% due to the consolidation of BIODLINK-B's financial statements, lower gross profit margins, additional finance costs, and the impact of foreign exchange costs from the depreciation of the USD against the RMB. The target price was cut from HKD83 to HKD80, while maintaining an 'Overweight' rating.
Nomura
NULL -> Buy
upgrade
2026-02-12
Reason
Nomura
Price Target
2026-02-12
upgrade
NULL -> Buy
Reason
Nomura lowered its 2025 revenue and profit forecasts for WUXI XDC by 4.5% and 8.7%, respectively, to reflect the actual data released by the company last month. Despite this adjustment, the broker anticipates a significant increase in profit for 2026, estimating a 47% rise. As a result, Nomura raised its target price for WUXI XDC from $82.72 to $87.73 and maintained a "Buy" rating, indicating a positive outlook based on expected future performance.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for 01875
Unlock Now

People Also Watch